Mytos, formerly Cytera CellWorks, was founded in 2016 to solve one of the last highly manual processes in biotech: growing human cells. Before its devices, cell culture used to be open, error-prone and labour-intensive.
To solve this, Mytos devices use the same T-flasks used in manual cell culture - so cells won't know the difference - and a closed system, meaning the internal infrastructure never comes into contact with non-sterile air. This is all configurable so it's easy for scientists to make changes to culturing protocols and schedules. Whilst lab automation is not new, especially in big pharma, it is mostly available for large-scale manufacturing of cell products. Lab automation companies, like Opentrons in the US, focus on more general applications such as pipetting.
In early 2023, Mytos launched its platform for Pharma customers, quickly gaining traction with partners that include five of the top US multi-billion dollar biotech companies. With a track record that includes collaborations with names like Orchard Therapeutics and, more recently, Aspen, Mytos is automating stem cell production for Parkinson's therapy. Backed by a strong group of investors, the company is firmly setting its sights on becoming a key player in biotech automation.
Steph
Company Specialist at Welcome to the Jungle
